Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$324.4MCash on Hand
CF+ Cash Runway
Follow OBX by emailGet an email when OBX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about OBX, unsubscribe in one click. Privacy
📣 What OBX Says Is Next
first half of 2027 · “NSCLC Phase 1 data are expected in the first half of 2027.”
Company press release, Nov 12, 2026 · SEC filing
first quarter of 2027 · “Enrollment in the registration-enabling cohort of the Phase 1/2 Agni-01 multicenter study of amsoki-cel in patients with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic melanoma is expected to be completed by the end of the first quarter of 2027, with topline data expected by the end of 2027.”
Company press release, Nov 12, 2026 · SEC filing
first quarter of 2027 · OBX-115: “We remain on track to complete enrollment in the registration-enabling cohort by the end of the first quarter of 2027 and report topline data by year-end 2027.” Third Quarter 2026 and Recent Updates Amsokigene autoleucel (amsoki-cel, formerly OBX-115)”
Company press release, Nov 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Clinical trial Reported Q3 2026 results: cash of $324.4 million as of September 30, 2026, net loss of $50.7 million or $1.23 per share, and runway into 2H 2028. Presented amsoki-cel melanoma data at SITC with a 67% ORR (10 of 15) and median PFS of 8.3 months, and appointed Mark Reisenauer to the Board. Form 8-K · SEC filing · Press release
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 12, 2026 ·
Financing Prospectus supplement registers up to 29,164,045 shares of common stock for resale by selling stockholders, with no proceeds to the company. Attaches the Q3 2026 10-Q filed November 12, 2026. Nasdaq closing price was $13.74 on November 10, 2026. Form 424B3 · SEC filing
Aug 28, 2026 ·
Obsidian reports stock-based compensation excluded from R&D and G&A expense: $0.7 million and $1.4 million for R&D in the three and six months ended June 30, 2026, and $0.8 million and $1.6 million for G&A in the same periods. Form S-1 · SEC filing
Aug 14, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Aug 14, 2026 ·
Earnings Obsidian filed an amendment with unaudited June 30, 2026 financial statements for Obsidian Therapeutics Sub, Inc. (formerly Obsidian Therapeutics, Inc.) and pro forma combined statements tied to the Mergers. Net loss for the six months ended June 30, 2026 was $45,497 thousand, versus $51,882 thousand a year earlier. Form 8-K/A · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jun 2029 · Phase 1/2 · Recruiting · Safety and Efficacy of OBX-115 in Advanced Solid Tumors Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
OBX holds $324.4M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Share count 61,774,046 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full OBX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OBX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.